Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12511127 | 0.93 | DPP4 (0.34) | DPP4DPP7 | |
| SCHEMBL18643327 | 0.82 | DPP4 (0.33) | DPP4DPP7 | |
| SCHEMBL12299810 | 0.79 | DPP4 (0.32) | DPP4DPP7 | |
| SCHEMBL14037256 | 0.77 | KDM4E (0.35) | DPP4DPP7 | |
| SCHEMBL12999357 | 0.76 | — | — | |
| SCHEMBL14399861 | 0.72 | TSHR (0.30) | — | |
| SCHEMBL10220630 | 0.71 | LRRK2 (0.30) | — | |
| SCHEMBL19969057 | 0.71 | MAPT (0.36) | — | |
| SCHEMBL25161908 | 0.70 | NPC1 (0.57) | — | |
| SCHEMBL22545669 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683291-B2 | Heterocyclic compounds for the treatment of disease | OPPILAN PHARMA LTD. (GB) | 2020-06-16 | — | — | US | disclosed |
| US-20190241556-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | OPPILAN PHARMA LTD. (GB) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241556-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, FH, TPMT | DPP4 2397/4885DPP7 2386/4885 |
| US-10683291-B2 | Heterocyclic compounds for the treatment of disease | VHL, FH, TPMT | DPP4 2397/4885DPP7 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.